If you’re considering treatment for yourself or a loved one, it’s reasonable to ask: does this actually work? For buprenorphine treatment, the research answer is about as clear as it gets in addiction medicine. Buprenorphine is one of only three medications approved by the FDA specifically for opioid use disorder, and it has been studied in large national datasets, federal claims data, and peer-reviewed clinical trials for more than two decades. The numbers consistently point the same direction.

The single biggest number: fewer overdose deaths

The most important outcome in opioid use disorder treatment is survival, and this is where buprenorphine’s data is strongest. A large NIH-funded study of adults who survived a nonfatal opioid overdose in Massachusetts found that starting buprenorphine afterward was associated with a 38% drop in opioid-related deaths over the following year, and methadone was associated with a 59% drop. A separate federal analysis of Medicare disability beneficiaries who survived an overdose found an even larger effect for buprenorphine specifically — roughly a 52–62% reduction in the odds of a subsequent fatal overdose, depending on the analysis.

A broader national study following more than 40,800 people in community-based treatment found that starting buprenorphine or methadone was linked to a 76% reduction in overdose risk within the first three months, and a 59% reduction that held at the one-year mark. That same study found meaningfully fewer emergency department and ICU visits among patients on medication, compared to those who weren’t.

Remission and treatment retention

A large retrospective study using medical records from nearly 92 million patients compared outcomes for people with opioid use disorder who were prescribed buprenorphine-naloxone against those who weren’t. The group on medication saw close to 34% fewer deaths within a year of diagnosis, and a remission rate roughly 1.9 times higher than the comparison group. Even after adjusting the two groups to be as similar as possible on age, sex, and other factors, the medication group still showed significantly better outcomes on both measures.

Retention — simply staying in treatment — matters because the protective effect of buprenorphine depends on consistent use. Clinical guidance published in American Family Physician notes that buprenorphine achieves a treatment retention rate above 50% at one year, a strong figure in a field where dropout is historically one of the biggest challenges. This is part of why medication-assisted treatment pairs medication with counseling and structured follow-up: staying engaged in care is what allows the medication’s benefits to hold.

Safety, even with fentanyl in the drug supply

One common concern is whether a medication like buprenorphine could itself become part of the overdose problem. The data says no. A joint NIDA and CDC analysis of national overdose death data found that buprenorphine was involved in just 2.2% of all overdose deaths during a two-year study period, even as prescribing access expanded. Researchers noted that most people who died of any opioid overdose, including those involving buprenorphine, had no evidence of being in current treatment at all — underscoring that the danger lies in the absence of treatment, not its presence.

Because illicit fentanyl has changed the opioid landscape significantly, dosing has evolved too. Research funded by the National Institutes of Health found that adults receiving higher buprenorphine doses had a lower rate of subsequent emergency visits related to behavioral health than those on the standard recommended dose — a finding that’s shaped how physicians think about dosing in the fentanyl era.

What this means in practice

Statistics describe populations, not any one person’s path — but the direction of the evidence is unusually consistent for a treatment in behavioral health: lower risk of fatal overdose, higher rates of remission, meaningful retention in care, and a strong safety record even as prescribing has expanded. That’s the foundation our clinical team builds on every day.

At Miami Valley Recovery, buprenorphine is offered alongside real counseling, case management, and options like Suboxone, Sublocade, and Brixadi depending on what fits a person’s life and clinical needs. If you’re weighing whether medication-assisted treatment is right for you or someone you love, the research is a reasonable place to start — and we’re glad to talk through what it could look like for you specifically.

Sources

National Institute on Drug Abuse (NIDA), news releases on medication-assisted treatment outcomes and overdose mortality · Annals of Internal Medicine, Larochelle et al., methadone and buprenorphine outcomes after nonfatal overdose · American Journal of Preventive Medicine, buprenorphine and overdose mortality in Medicare disability beneficiaries · JAMA Network Open, NIDA/CDC analysis of buprenorphine-involved overdose deaths · American Family Physician (2025), clinical guidance on buprenorphine treatment retention · Addiction Policy Forum, summary of Wakeman et al. community-based treatment cohort study